Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The High mobility group AT-hook 1 (HMGA1) messenger RNA 3' untranslated region (3'UTR) is a critical regulatory segment of the HMGA1 transcript that governs the stability and translation of the HMGA1 protein (Source: PubMed, PMID: 17434132). This region is notably long and contains multiple binding sites for the let-7 microRNA family, which normally suppresses HMGA1 expression (Source: Nature, doi:10.1038/nature02378). In many cancers, the HMGA1 3'UTR is truncated or lost due to chromosomal rearrangements, leading to protein overexpression and oncogenic transformation (Source: UniProt, P17096). Beyond its role as a cis-regulatory element, the HMGA1 3'UTR functions as a competing endogenous RNA (ceRNA), acting as a molecular sink for microRNAs and thereby regulating the expression of other genes involved in cell growth and metabolism (Source: Cell, doi:10.1016/j.cell.2011.07.034). Consequently, this mRNA region is an emerging therapeutic target for antisense oligonucleotides and small molecules designed to modulate HMGA1 levels or restore normal microRNA-mediated regulation in diseases such as cancer and type 2 diabetes (Source: NIH, PMC4133183). Targeting this region offers a strategy to indirectly control the HMGA1 protein, which is otherwise difficult to target directly due to its lack of a defined enzymatic pocket.
Antisense oligonucleotides (ASOs) target the 3'UTR to induce RNase H-mediated degradation or block regulatory protein binding, while microRNA mimics restore the natural inhibitory control over the transcript (Source: PubMed, PMID: 25053460).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on High mobility group AT-hook 1 messenger RNA 3' untranslated region (HMGA1 3'UTR).